TGF-β1 and hypoxia-dependent expression of MKP-1 leads tumor resistance to death receptor-mediated cell death

Cell Death and Disease

Volumn 4, Issue 2, 2013, Pages

  Park, J ^a   Lee, J ^a   Kang, W ^b   Chang, S ^a   Shin, E C ^a,b   Choi, C ^a,b  

^a Korea Advanced Institute of Science and Technology (KAIST)   (South Korea)

^b Graduate School of Medical Science and Engineering   (South Korea)

Author keywords

Cell death; Hypoxia; Mitogen activated protein kinase; Mitogen activated protein kinase phosphatase; Transforming growth factor; Tumor resistance

Indexed keywords

ANTINEOPLASTIC AGENT; DEATH RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE PHOSPHATASE 1; SMALL INTERFERING RNA; STRESS ACTIVATED PROTEIN KINASE; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL CELL; ARTICLE; BIOASSAY; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CELL DEATH; CELL SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOXIA; IMMUNE DEFICIENCY; IMMUNE EVASION; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL; TUMOR RESISTANCE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL HYPOXIA; CELL LINE, TUMOR; DATABASES, FACTUAL; DUAL SPECIFICITY PHOSPHATASE 1; HEP G2 CELLS; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; LIVER NEOPLASMS; MICE; MICE, TRANSGENIC; PHOSPHORYLATION; RECEPTORS, DEATH DOMAIN; RECOMBINANT PROTEINS; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SMAD2 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84875992383     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2013.42     Document Type: Article

References (39)

1. de Visser KE, Eichten A, Coussens LM. Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 2006; 6: 24-37.
2. Rabinovich GA, Gabrilovich D, Sotomayor EM. Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 2007; 25: 267-296.
3. Smyth MJ, Godfrey DI, Trapani JA. A fresh look at tumor immunosurveillance and immunotherapy. Nat Immunol 2001; 2: 293-299.
4. Drake CG, Jaffee E, Pardoll DM. Mechanisms of immune evasion by tumors. Adv Immunol 2006; 90: 51-81.
5. Dunn GP, Koebel CM, Schreiber RD. Interferons, immunity and cancer immunoediting. Nat Rev Immunol 2006; 6: 836-848.
6. Shi Y, Massague J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 2003; 113: 685-700.
7. Bodmer S, Strommer K, Frei K, Siepl C, de Tribolet N, Heid I et al. Immunosuppression and transforming growth factor-beta in glioblastoma. Preferential production of transforming growth factor-beta 2. J Immunol 1989; 143: 3222-3229.
8. von Bernstorff W, Voss M, Freichel S, Schmid A, Vogel I, Johnk C et al. Systemic and local immunosuppression in pancreatic cancer patients. Clin Cancer Res 2001; 7(3 Suppl): 925s-932s.
9. Hersey P. Impediments to successful immunotherapy. Pharmacol Ther 1999; 81: 111-119.
10. Yang L, Pang Y, Moses HL. TGF-beta and immune cells: an important regulatory axis in the tumor microenvironment and progression. Trends Immunol 2010; 31: 220-227.
11. Massague J. TGFbeta in Cancer. Cell 2008; 134: 215-230.
12. Tong XK, Hamel E. Transforming growth factor-beta 1 impairs endothelin-1-mediated contraction of brain vessels by inducing mitogen-activated protein (MAP) kinase phosphatase-1 and inhibiting p38 MAP kinase. Mol Pharmacol 2007; 72: 1476-1483.
13. Owens DM, Keyse SM. Differential regulation of MAP kinase signalling by dual-specificity protein phosphatases. Oncogene 2007; 26: 3203-3213.
14. Mikami F, Lim JH, Ishinaga H, Ha UH, Gu H, Koga T et al. The transforming growth factorbeta- Smad3/4 signaling pathway acts as a positive regulator for TLR2 induction by bacteria via a dual mechanism involving functional cooperation with NF-kappaB and MAPK phosphatase 1-dependent negative cross-talk with p38 MAPK. J Biol Chem 2006; 281: 22397-22408.
15. Patterson KI, Brummer T, O'Brien PM, Daly RJ. Dual-specificity phosphatases: critical regulators with diverse cellular targets. Biochem J 2009; 418: 475-489.
16. Deng Y, Ren X, Yang L, Lin Y, Wu XA. JNK-dependent pathway is required for TNFalphainduced apoptosis. Cell 2003; 115: 61-70.
17. Krueger A, Baumann S, Krammer PH, Kirchhoff S. FLICE-inhibitory proteins: regulators of death receptor-mediated apoptosis. Mol Cell Biol 2001; 21: 8247-8254.
18. Schmitz I, Kirchhoff S, Krammer PH. Regulation of death receptor-mediated apoptosis pathways. Int J Biochem Cell Biol 2000; 32: 1123-1136.
19. Kischkel FC, Lawrence DA, Chuntharapai A, Schow P, Kim KJ, Ashkenazi A. Apo2L/ TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity 2000; 12: 611-620.
20. Chen G, Goeddel DV. TNF-R1 signaling: a beautiful pathway. Science 2002; 296: 1634-1635.
21. Wajant H, Pfizenmaier K, Scheurich P. Tumor necrosis factor signaling. Cell Death Differ 2003; 10: 45-65.
22. Shen HM, Pervaiz S. TNF receptor superfamily-induced cell death: redox-dependent execution. Faseb J 2006; 20: 1589-1598.
23. Davis RJ. Signal transduction by the JNK group of MAP kinases. Cell 2000; 103: 239-252.
24. Muppidi JR, Tschopp J, Siegel RM. Life and death decisions: secondary complexes and lipid rafts in TNF receptor family signal transduction. Immunity 2004; 21: 461-465.
25. Chauhan D, Li G, Hideshima T, Podar K, Mitsiades C, Mitsiades N et al. JNK-dependent release of mitochondrial protein, Smac, during apoptosis in multiple myeloma (MM) cells. J Biol Chem 2003; 278: 17593-17596.
26. Nakano H. Signaling crosstalk between NF-kappaB and JNK. Trends Immunol 2004; 25: 402-405.
27. Lin A. Activation of the JNK signaling pathway: breaking the brake on apoptosis. Bioessays 2003; 25: 17-24.
28. Elliott RL, Blobe GC. Role of transforming growth factor Beta in human cancer. J Clin Oncol 2005; 23: 2078-2093.
29. Yau T, Chan P, Epstein R, Poon RT. Management of advanced hepatocellular carcinoma in the era of targeted therapy. Liver Int 2009; 29: 10-17.
30. Yu H, Park J, Lee J, Choi K, Choi C. Constitutive expression of MAP kinase phosphatase-1 confers multi-drug resistance in human glioblastoma cells. Cancer Res Treat 2012; 44: 195-201.
31. Yousefi S, Conus S, Simon HU. Cross-talk between death and survival pathways. Cell Death Differ 2003; 10: 861-863.
32. Heyninck K, Beyaert R. Crosstalk between NF-kappaB-activating and apoptosis-inducing proteins of the TNF-receptor complex. Mol Cell Biol Res Commun 2001; 4: 259-265.
33. Liotta LA, Kohn EC. The microenvironment of the tumour-host interface. Nature 2001; 411: 375-379.
34. Moutsopoulos NM, Wen J, Wahl SM. TGF-beta and tumors-an ill-fated alliance. Current Opin Immunol 2008; 20: 234-240.
35. Hong S, Lim S, Li AG, Lee C, Lee YS, Lee EK et al. Smad7 binds to the adaptors TAB2 and TAB3 to block recruitment of the kinase TAK1 to the adaptor TRAF2. Nat Immunol 2007; 8: 504-513.
36. Hong S, Lee C, Kim SJ. Smad7 sensitizes tumor necrosis factor induced apoptosis through the inhibition of antiapoptotic gene expression by suppressing activation of the nuclear factor-kappaB pathway. Cancer Res 2007; 67: 9577-9583.
37. Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor beta in human disease. N Engl J Med 2000; 342: 1350-1358.
38. Semenza GL. Oxygen sensing, homeostasis, and disease. N Engl J Med 2011; 365: 537-547.
39. Park J, Kang W, Ryu SW, Kim WI, Chang DY, Lee DH et al. Hepatitis C virus infection enhances TNFalpha-induced cell death via suppression of NF-kappaB. Hepatology 2012; 56: 831-840.